Characteristics of residual invasive breast cancer after neoadjuvant therapy in the KATHERINE study

被引：2
|
作者：
Mamounas, E. P. [1 ]
机构：
[1] Orlando Hlth Canc Inst, NSABP Fdn & Dept Surg, Orlando, FL USA
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷 / 09期
关键词：
TRASTUZUMAB; DISEASE; T-DM1;
D O I：
10.1016/j.annonc.2021.05.802
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1191 / 1192
页数：2
相关论文
共 50 条
  • [11] Prognostic value of the residual cancer burden after neoadjuvant chemotherapy for invasive lobular breast cancer: An international pooled cohort study
    Gottipati, S.
    Earl, H. M.
    Yau, C.
    Cameron, D. A.
    Abraham, J.
    Hayward, L.
    Reyal, F.
    Osdoit, M.
    Sonke, G. S.
    Wesseling, J.
    Boughey, J.
    Goetz, M. P.
    DeMichele, A.
    Pusztai, L.
    Sharma, P.
    Martin Jimenez, M.
    Lopez-Tarruella Cobo, S.
    Del Monte-Millan, M.
    Symmans, F.
    Mukhtar, R.
    ANNALS OF ONCOLOGY, 2023, 34 : S325 - S326
  • [12] Validation of Residual Cancer Burden as Prognostic Factor for Breast Cancer Patients After Neoadjuvant Therapy
    Mueller, Hannah Deborah
    Posch, Florian
    Suppan, Christoph
    Bargfrieder, Ute
    Gumpoldsberger, Melanie
    Hammer, Robert
    Hauser, Hubert
    Dandachi, Nadia
    Prein, Kurt
    Stoeger, Herbert
    Lax, Sigurd
    Balic, Marija
    ANNALS OF SURGICAL ONCOLOGY, 2019, 26 (13) : 4274 - 4283
  • [13] Validation of Residual Cancer Burden as Prognostic Factor for Breast Cancer Patients After Neoadjuvant Therapy
    Hannah Deborah Müller
    Florian Posch
    Christoph Suppan
    Ute Bargfrieder
    Melanie Gumpoldsberger
    Robert Hammer
    Hubert Hauser
    Nadia Dandachi
    Kurt Prein
    Herbert Stoeger
    Sigurd Lax
    Marija Balic
    Annals of Surgical Oncology, 2019, 26 : 4274 - 4283
  • [14] Residual Disease After Neoadjuvant Chemotherapy for Breast Cancer
    Morris, Gloria J.
    Robinson, Patricia A.
    Lo, Shelly
    Samuel, Thomas A.
    Sheikh, Asad A.
    Jordan, W. Edward, III
    Thomas, Lisa C.
    Kiel, Krystyna
    Peters, Christopher A.
    SEMINARS IN ONCOLOGY, 2010, 37 (01) : 1 - 10
  • [15] Effectivness of breast-conserving treatment for minimal residual tumors after neoadjuvant breast cancer therapy
    Pesotsky, R.
    Semiglazov, V.
    Ereschenko, S.
    Bessonov, A.
    Emelyanov, A.
    Tabagua, T.
    Komyahov, A.
    Ivanova, O.
    Zhiltsova, E.
    Nikolaev, K.
    Levchenko, V.
    Zirov, K.
    Krivorotko, P.
    BREAST, 2021, 56 : S61 - S61
  • [16] Transcriptomic changes in invasive residual cancer after neoadjuvant chemotherapy in patients with triple-negative breast cancer
    Orozco, Javier
    Manughian-Peter, Ayla
    Gago, Francisco
    Chang, Grace
    Grumley, Janie
    Marzese, Diego
    ANNALS OF SURGICAL ONCOLOGY, 2019, 26 : 23 - 24
  • [17] Outcomes of Invasive Breast Cancer after Neoadjuvant Therapy and Its Association with Molecular Profiles
    Boone, J.
    Tawfik, O. W.
    Fan, F.
    MODERN PATHOLOGY, 2013, 26 : 31A - 31A
  • [18] Outcomes of Invasive Breast Cancer after Neoadjuvant Therapy and Its Association with Molecular Profiles
    Boone, J.
    Tawfik, O. W.
    Fan, F.
    LABORATORY INVESTIGATION, 2013, 93 : 31A - 31A
  • [19] The percentage of residual DCIS in patients diagnosed with primary invasive breast cancer treated with neoadjuvant systemic therapy: A nationwide retrospective study
    Ploumen, R. A. W.
    Keymeulen, K. B. M., I
    Kooreman, L. F. S.
    van Kuijk, S. M. J.
    Siesling, S.
    Smidt, M. L.
    van Nijnatten, T. J. A.
    EJSO, 2022, 48 (01): : 60 - 66
  • [20] Association of Residual Cancer Burden After Neoadjuvant Therapy and Event-Free Survival in Breast Cancer
    Huang Xiaomei
    Liu Zaiyi
    JAMA ONCOLOGY, 2022, 8 (04) : 645 - 646
12345